AIxCrypto Holdings (AIXC) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
8 Aug, 2026Executive summary
RoboShare, an on-demand robot sharing marketplace, was launched and prioritized for the second half of 2026, with a Los Angeles pilot set for August and first commercial deliveries targeted for Q3 2026.
The company shifted from strategic planning to focused execution, emphasizing commercialization, expense discipline, and digital infrastructure development.
Strategic realignment completed, with legacy biotechnology business discontinued as of May 2026.
Significant $12.0 million investment in Faraday Future completed in April 2026, classified as parent company equity held at cost.
Financial highlights
Q2 2026 operating expenses were $2,959,325, down 32% from Q1 2026 but up from $1,683,747 in Q2 2025.
Net loss for Q2 2026 was $4,187,605, an improvement from $6,079,016 in Q1 2026 but higher than $1,687,003 in Q2 2025.
Net loss per share was $(0.21) for Q2 2026; total operating expenses for six months were $7,290,000, with a net loss of $10,270,000.
Cash and cash equivalents were $577,328 at June 30, 2026, with $5,212,903 in digital assets; total assets declined to $7,400,000 from $31,300,000 at year-end 2025.
No revenue was reported for Q2 2026; net loss on digital assets was $984,364 in Q2 2026.
Outlook and guidance
Initial RoboShare revenue is expected in Q3 2026, with month-over-month growth anticipated as platform activity scales.
Expansion into additional markets will depend on pilot performance and local conditions.
Management expects continued net losses and negative cash flow from operations, with substantial doubt about the ability to continue as a going concern.
No specific full-year revenue or expense guidance provided.
Latest events from AIxCrypto Holdings
- Net loss narrowed, but severe liquidity and going concern risks persist despite new capital raised.AIXC
Q4 2024 - Raising up to $4M for cancer drug development, with high dilution and Nasdaq delisting risk.AIXC
Registration filing - Clinical-stage cancer drug developer seeks up to $4M via equity offering amid financial risks.AIXC
Registration filing - Cancer therapeutics firm seeks up to $1.8M via share/warrant offering amid high financial risk.AIXC
Registration filing - Liquidity crisis persists as cash runs low, with urgent need for financing to avoid delisting.AIXC
Q1 2024 - Cancer drug developer seeks up to $3.7M via share/warrant offering amid Nasdaq delisting risk.AIXC
Registration filing - 2025 net loss widened to $16.97M amid strategic realignment and ongoing liquidity risks.AIXC
Q4 2025 - Net loss narrowed, but liquidity and going concern risks remain acute amid ongoing cash burn.AIXC
Q3 2024 - Severe liquidity challenges persist as net loss grows and cash reserves dwindle, with going concern doubts.AIXC
Q1 2025